June, 2024

article thumbnail

Speaking a Second Language Has Countless Benefits in the Pharmacy Setting

Pharmacy Times

Being able to communicate in a different language can improve treatment adherence and medication efficacy outcomes

article thumbnail

Slideshow: Everything You Need to Know About the US Bird Flu Outbreak

Drug Topics

In a webinar conducted by the National Foundation for Infectious Diseases (NFID), experts gathered to publicly address the ongoing bird flu outbreak across many US states.

223
223
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Surgeon general declares gun violence a public health crisis

STAT

Firearm violence is officially a public health crisis in the U.S. — Surgeon General Vivek Murthy says so. In a new advisory published on Tuesday, Murthy calls attention to the health toll of gun violence, describing the size of the crisis while laying out a roadmap of research and policy interventions to curb its effects. “My hope is that framing just the profound impact and pervasive impact of gun violence in our country … can firmly take it out of the realm of politics and

145
145
article thumbnail

Modifier gene therapy – clinical development and manufacturing considerations

European Pharmaceutical Review

Tell us about Ocugen’s lead programme, OCU400. What’s the latest and what’s next? OCU400 is a modifier gene therapy aimed at treating retinitis pigmentosa and Leber congenital amaurosis (LCA). In April 2024, Ocugen received US Food and Drug Administration (FDA) clearance to initiate the Phase III liMeliGhT clinical trial for OCU400 for retinitis pigmentosa.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Supreme Court overrules Chevron deference, dealing blow to federal healthcare agencies

Fierce Healthcare

The U.S. Supreme Court, by a vote of 6-3, has overturned the Chevron deference, stripping power from federal agencies to interpret and enforce regulations. | The U.S. Supreme Court is overruling long-standing precedent. Here's how it could affect healthcare policy.

143
143
article thumbnail

Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention

Fierce Pharma

For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. | For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. For Gilead, it serves as one of two pieces for a potential FDA filing. For GSK, it means a major competitor could be looming around the corner.

FDA 144

More Trending

article thumbnail

Cannabis to Treat Cancer: Younger Populations Reluctant to Disclose as Overall Use Becomes More Accepted

Drug Topics

Researchers addressed the use of cannabis to treat cancer symptoms in rural and urban areas, as well as patients’ comfortability discussing it with their providers.

219
219
article thumbnail

Three months into bird flu outbreak in U.S. dairy cows, experts see deep-rooted problems in response

STAT

Three months since an outbreak of avian influenza in U.S. dairy cattle was declared, the country is failing to take the necessary steps to get in front of the virus and possibly contain its spread among cows, according to interviews with more than a dozen experts and current and former government officials. The country still does not have a sufficient testing infrastructure in place, nor a full understanding of how the virus is moving within herds and to new herds, experts say.

145
145
article thumbnail

Novavax seeks FDA approval for updated Covid-19 vaccine

Pharmaceutical Technology

Novavax has sought US FDA approval for an updated JN.1 version of its Covid-19 vaccine, NVX-CoV2705, for individuals aged 12 years and above.

Vaccines 145
article thumbnail

2024 shaping up to be a big year for healthcare AI companies. But some investors remain cautious

Fierce Healthcare

AI deal activity is dominating healthcare investment with one in four dollars invested in healthcare going toward companies leveraging AI, according to a new report. | So far, in 2024, $2.8 billion has already been invested in AI healthcare companies, with SVB projecting the sector to see $11.

139
139
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Daiichi’s lung cancer ADC rejected by FDA in blow to first project under Merck partnership

Fierce Pharma

In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody drug conjugate (ADC) patritumab deruxtecan. | In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody drug conjugate patritumab deruxtecan.

FDA 137
article thumbnail

Implications for Pharmacies Navigating Shared Clinical Decision-Making in Vaccination

Pharmacy Times

The SCDM model demands more than the traditional roles assigned to pharmacists, requiring an enhanced level of patient engagement, medical knowledge, and legal authority to implement effectively

Vaccines 149
article thumbnail

‘Skinny jabs’: weight-loss drugs set for new boom as generic versions emerge

The Guardian - Pharmaceutical Industry

Alternatives to costly Wegovy and Saxenda will make such treatments more widely available worldwide Ozempic maker invests $4bn to meet US ‘skinny jab’ demand Medicines that enable dramatic weight loss are set to experience a new boom in uptake, experts have said, as the first generic versions hit the market this week at a lower cost than the original drugs.

125
125
article thumbnail

Opinion: Long Covid feels like a gun to my head

STAT

I have spent my career studying infectious diseases that fall under the heading of neglected tropical diseases. Now I have a neglected disease — long Covid — an incurable (for now and for me) disease. As a medical anthropologist working in global health, I thought I understood the despair of poor health. I didn’t. I join 7% of the U.S. adult population — or about 18 million Americans — who have experienced long Covid.

145
145
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

Pharmafile

AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been approved in Japan for the first line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumours have exon 19 deletions or exon 21 mutations.

article thumbnail

Color Health taps OpenAI to generate screening plans for cancer patients

Fierce Healthcare

Color Health is working with OpenAI to test out computer-generated personalized care plans for cancer patients. | Color developed a new copilot app that leverages GPT-4o to identify missing diagnostics and create tailored workup plans for patients.

136
136
article thumbnail

After 33 years, Geron finally crosses FDA finish line with blood cancer med Rytelo

Fierce Pharma

Once hailed as an anti-aging magic bullet, telomerase has failed to live up to the hype as it was profiled in a | The FDA has approved Geron Corporation's Rytelo (imetelstat) to treat a group of bone marrow disorders called myelodysplastic syndrome (MDS). The approval is the first for the 33-year-old California biotech.

FDA 135
article thumbnail

Researchers Find Shared Multiomic Molecular Dysregulations in Brains With PTSD and MDD

Pharmacy Times

The investigators are optimistic that the data can establish stress-related pathways while revealing potential therapeutic options for patients with major depressive disorder and post-traumatic stress disorder.

149
149
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Avoiding the pharma ‘junk pile’ with launch readiness, pipeline rigor and ‘quick kills’

PharmaVoice

Drug launches have underperformed expectations at a high rate, and pharmas need to get better at thinning the pipeline to make room for the real wins, says a life sciences consultant.

120
120
article thumbnail

STAT+: Vertex reports positive results in stem cell trial for type 1 diabetes

STAT

ORLANDO — Twelve people with type 1 diabetes who received a therapy derived from stem cells were able to produce enough of their own insulin to maintain healthy blood glucose levels 90 days later, Vertex Pharmaceuticals said Friday. All but one reduced or eliminated the need to inject insulin over those three months and three people followed for one year no longer needed to inject insulin at all.

144
144
article thumbnail

New polymer-based drug delivery system developed for tuberculosis

European Pharmaceutical Review

Researchers have reported the successful formulation of clofazimine spray-dried poly (lactic acid-co-glycolic acid) (PLGA) microparticles as an “efficient” treatment for tuberculosis (TB). In treating this bacterial infection, the paper highlighted that oral therapy often fails to achieve therapeutic concentrations at the primary infection site, the lungs.

119
119
article thumbnail

National Nurses United pushes back against deployment of ‘unproven’ AI in healthcare

Fierce Healthcare

The nation’s largest nurses union is demanding that artificial intelligence tools used in healthcare be proven safe and equitable before deployment. | A union organization for nurses nationwide says the deployment of AI in healthcare will push nurses out of patient rooms and compromise patient safety. A new AI Bill of Rights lays out nurse and patient protections, which are not currently being met.

137
137
article thumbnail

Europe taps CSL Seqirus to produce bird flu vaccines for pandemic preparedness efforts

Fierce Pharma

Right after signing on to help with bird flu pandemic preparedness efforts in the U.S., CSL Seqirus has agreed to do the same in Europe through a vaccine supply pact. | The vaccine maker will deliver 665,000 doses of its avian flu-matched pre-pandemic vaccine. Under a 4-year contract, authorities can purchase up to 40 million doses.

Vaccines 133
article thumbnail

During Drug Shortages, There Are Resources so Pharmacists ‘Never Need to Ration Life-Saving Drugs’

Pharmacy Times

Laura Bray, founder of Angels for Change, explains that addressing the 4 key economic causes to drug shortages can also help lead to effective solutions long-term.

145
145
article thumbnail

Why progress on ovarian cancer treatments is slow

pharmaphorum

Progress on ovarian cancer treatments has been slow, despite promising drugs like Keytruda and Lynparza. Learn about the obstacles and challenges in developing effective treatments for this deadly disease.

122
122
article thumbnail

Inside Anthony Fauci’s ‘On Call’: 9 health and science takeaways from the memoir of America’s most famous doctor

STAT

Anthony Fauci spent 40 years in the top echelons of government. It was no accident. To read the forthcoming memoir by the country’s former top infectious disease expert, “On Call: A Doctor’s Journey in Public Service,” a copy of which was obtained by STAT, is to get a sense of his finesse while advising seven presidents. He strove, he writes, to speak with complete candor and stay out of politics, while remaining strategic in pushing for policies he considered vital t

145
145
article thumbnail

First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment

Pharmafile

Assembly Biosciences has announced that the first participant has been dosed in its phase 1b trial of ABI-4334, the company’s next-generation capsid assembly modulator (CAM) candidate currently being developed for the treatment of chronic hepatitis B virus (HBV) infection. The post First patient dosed in Assembly Biosciences’ phase 1b trial for hepatitis B treatment appeared first on Pharmafile.

116
116
article thumbnail

Amazon Pharmacy expands RxPass subscription service to Medicare patients

Fierce Healthcare

Amazon Pharmacy is expanding its prescription drug subscription program, called RxPass, to Prime members on Medicare insurance. | The RxPass program, launched in January 2023, provides unlimited access to 60 eligible generic medications and will ship the medications to customers' homes for a flat monthly fee of $5.

Insurance 135
article thumbnail

BMS chief Boerner says company is still hungry for deals after spending more than $20B on M&A last year

Fierce Pharma

As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target | As some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target comes along.

136
136
article thumbnail

Understanding the Connection Between Genetic Risk and Brain Cell Activity in Autism Spectrum Disorder

Pharmacy Times

Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.

156
156
article thumbnail

Pharmacogenomics and IVDR: Overcoming transition challenges

pharmaphorum

Understanding the challenges and opportunities in transitioning to IVDR for pharmacogenomics can be complex. Learn more about how to overcome these challenges effectively.

126
126
article thumbnail

Four Tops singer’s lawsuit says he visited ER for chest pain, ended up in straightjacket

STAT

When Alexander Morris, a member of the Motown group The Four Tops , visited a Detroit-area Ascension hospital with chest pain and trouble breathing, he said the staff assumed he was mentally ill after he told them he was a famous singer. Instead of treating Morris, a white security guard told him to “sit his Black ass down” and he was placed in a straightjacket, Morris claims in a new lawsuit.

Hospitals 145
article thumbnail

Ahead of its upcoming decision date, a competitor takes aim at KarXT

PharmaVoice

The FDA isn’t slated to render a decision about BMS and Karuna’s potential breakthrough schizophrenia med until September — but a biotech is already hoping to be hot on its heels.

FDA 115